Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate

Annals of Clinical Biochemistry

Volumn 36, Issue 4, 1999, Pages 523-525

  Beghin, L ^a   Capps, N ^b   Duhal, N ^c   Davies, J ^b   Staels, B ^a   Luc, G ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Hyperlipidaemia; Kinetic study; Stable isotope

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CIPROFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CASE REPORT; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032775406     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329903600420     Document Type: Article

References (17)

1. 1 Chandler HA, Batchelor AJ. Ciprofibrate and lipid profile. Lancet 1994; 344: 128-9
2. 2 Capps NE. Lipid profiles on fibric-acid derivatives. Lancet 1994; 344: 684-5
3. 3 McLeod AJ, Warren RJ, Armitage M. Abnormal lipid profiles on fibrate derivatives. Lancet 1996; 347: 261
4. 4 Murphy MJ, Packard CJ, Oreilly DS. Fibrates and HDL cholesterol. Ann Clin Biochem 1997; 34: 114
5. 5 Collinson PO, Hjelm CJ, Canepaanson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996; 33: 159-61
6. 6 McLeod AJ, Warren RJ, Armitage M. Ciprofibrate and lipid profile. Lancet 1994; 344: 955
7. 7 Oleesky DA, Mir MA. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem 1997; 34: 573-4
8. 8 Elkhalil L, Majd Z, Bakir R, Perez-Mendez O, Castro G, Poulain P, et al. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism 1997; 46: 474-83
9. 9 Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 1998; 47: 484-92
10. 13C)KIC in plasma by capillary gas chromatography/mass spectrometry in protein turnover studies. Biomed Mass Spectrom 1985; 12: 432-6
11. 11 Saku K, Gartside PS, Hynd BA, Mendoza SG, Kashyap ML. Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism 1985; 34: 754-64
12. 12 Le NA, Ginsberg HN. Heterogeneity of apolipoprotein A-I turnover in subjects with reduced concentrations of plasma high density lipoprotein cholesterol. Metabolism 1988; 37: 614-7
13. 13 Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB. Evaluation of apo A-I kinetics in humans using simultaneous stable isotope and exogenous radiotracer methods. J Lipid Res 1993; 34: 2207-15
14. 14 Fisher WR, Venkatakrishnan V, Zech LA, Hall CM, Kilgore LL, Stacpoole PW, et al. Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J Lipid Res 1995; 36: 1618-28
15. 15 Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial. Atherosclerosis 1985; 55: 161-9
16. 16 Kashyap ML, Saku K. HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil. Adv Exp Med Biol 1991; 285: 233-6
17. 17 Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, et al. Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 1984; 74: 2164-77